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Ongoing concerns over the presence and persistence of antimicrobial resistance (AMR), particularly in Gram-
negative bacteria, continue to have significant global health impacts. The gastrointestinal tract, or ‘gut’, en-
vironment amplifies AMR in the human gut microbiome, even in the absence of antibiotics. It constitutes a
complex and diverse community of organisms, and patterns and alterations within it are increasingly being
found to be associated with states of health and disease. Our understanding of the effects of routes of admin-
istration of antimicrobials on the gut microbiome is still lacking despite recent advances in metagenomics. In
this article we review current evidence for antibiotic effects on gutmicrobiota and explore possible prescribing
and stewardship approaches that would seek to minimize these effects. If we are to preserve existing and
new antimicrobials, we need to consider their use in the context of their effect on gut ecology, and the human
microbiome in general.
Introduction
The ongoing emergence of antimicrobial resistance (AMR), particu-
larly in Gram-negative bacteria, is of major global concern. The
gastrointestinal tract, or ‘gut’, microbiome is known to be an im-
portant ‘amplifier’ of AMR, even in the absence of antibiotics.
Patterns and alterations within it are increasingly being found to
be associated with states of health and disease. The inability of
commonly prescribedantimicrobials to precisely target specificmi-
crobial species results in decreased bacterial diversity and load and
has the potential to cause overgrowth of resistant bacteria.1,2
Despite recent advances in technology and, with it, a wealth of lit-
erature, the concept of the gutmicrobiome is not a new one. Nord
et al.3 considered the impact of antimicrobial agents on ‘normal’
gut flora, using culture-based methods, in the 1980s; in particular
they warned about the use of anti-anaerobe agents resulting in
colonization of the gut by Gram-positive and Gram-negative bac-
teria. Indeed, the use of selective decontamination of the digestive
tract (SDD) was already being discussed within the context of
maintaining gut ‘ecology,’ limiting new colonizationwith endogen-
ous and exogenous organisms and preventing sepsis in high-risk
patients.4 For the purposes of this review article, we will mostly
focus on data using emerging technologies, although we acknow-
ledge the ongoing and historical use of culture-based methods to
support this.
When antibiotic therapy is required, the current global para-
digm favours the use of oral administration, whenever it is possible
and safe to do so, with the main goals of: (i) reducing
complications of intravenous (iv) access devices, including infec-
tions; (ii) avoiding hospital admission and promoting hospital dis-
charge; (iii) reducing economic costs; and (iv) facilitating patient
recovery and convenience. To date, the potential differential
effects of antibiotic administration route on the gut microbiome
have not influenced this paradigm and it remains unclear as to
what extent they should.
Zhang et al.2 challenged the oral paradigm in a mouse model.
They found that oral administration of amoxicillin and tetracycline
increased the development of AMR genes to a greater extent com-
pared with the same antibiotics administered iv and had differen-
tial effects on the gut microbiota. The existing clinical approach of
oral administration of antimicrobials whenever possible is un-
doubtedly robust in most circumstances. However, the potential
differential impact of the route of antibiotic administration on the
gut microbiome is worthy of consideration with respect to the fol-
lowing: (i) understanding the size and length of this effect for dif-
ferent agents, the clinical consequences thereof, and the
antimicrobial prescribing and stewardship implications of such
effects; (ii) the importance of developing novel routes of antibiotic
administration that are clinically effective, but result in lower gut
microbiome exposure;2 and (iii) the need for highly specific, very
narrow-spectrum (precision) antimicrobials that have less impact
on the gutmicrobiome.
In this article, we discuss how antibiotics affect the gut micro-
biome and why this is important, and consider the potential roles
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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of different approaches to antimicrobial prescribing and steward-
ship, and of novel therapeutics in moderating antibiotic-
associated adverse effects on the gut.
The effect of antibiotics on the gut
microbiome
Within our gastrointestinal tract there are1011–1012microorgan-
isms per gramof content and.1000 different species,5–7with each
individual person carrying at least 160 species.7 Early attempts at
defining the gut microbiome were culture-dependent and only
revealed an estimated 10%–30% of the gut microbiota.8 PCR tech-
niques and Sanger sequencing furthered our understanding of
unculturable organisms.7,9 The study of gut microbial diversity by
Eckburg et al.10 using metagenomic techniques improved our
understanding of both the gut microbiome and the potential im-
portance ofmetagenomic approaches. The sixmain bacterial phyla
found within the gut are Firmicutes, Bacteroidetes, Actinobacteria,
Fusobacteria, Proteobacteria and Verrucomicrobia, with the vast
majority of gut commensal bacteria being anaerobes.11,12
The development of the gut microbiome is a complex process.
Whilst there is a reasonably predictable acquisition of species dur-
ing early childhood, this may be impacted by timing and route of
delivery at birth, breast milk, diet and environment.13–17 Early use
of antimicrobial agentsmay have a lasting impact on the develop-
ingmicrobiome and its host, affecting the host’s metabolome and
immune system and thereby their health and disease states later
in life. Arrieta et al.18 found that inoculation of germ-freemicewith
bacteria found to be deficient in children at risk of asthma amelio-
rated airway inflammation; antibiotic exposure in the first year of
life was a significant environmental factor in these children. Cox
et al.19 demonstrated that while low-dose oral penicillin adminis-
tered tomice in early life may not lead to a prolonged reduction in
microbial diversity or abundance, significant differences in adipos-
ity, metabolism and immune function still occur subsequently and
are associated with alterations in the characteristics of the bacter-
ial population within the gut microbiome. This suggests that early
microbial alterationsmay continue to affect later humanmetabol-
ism and health. Gut microbial alterations and their effect on host
metabolism and immunity are increasingly associated with non-
infection disease states such as inflammatory bowel disease, dia-
betes, rheumatological conditions, respiratory dysfunction, cancer
(where it has been shown to impact the host’s response to chemo-
therapy), drug metabolism, mental health and recovery after spi-
nal cord injury.18–25 Understanding and protecting this microbial
community and learning how to manipulate it to provide novel
therapeutic strategies and optimize host response to therapy
should therefore be of interest to all medical and surgical
specialties.
Numerous studies have demonstrated a reduction in microbial
diversity and colonization resistance to potential pathogens, such
as Clostridioides (Clostridium) difficile, in response to antimicrobial
exposure.1,6,16,26–28 Culture-based methods demonstrated rela-
tively short-term impacts, finding that ‘normalization’ of the gut
microbiota generally occurred within 4 weeks of antibiotic ther-
apy.3,5,27–30 However, we now have the ability to sequence the re-
mainder of the gut microbiota, which has been challenging to
culture to date. Adamsson et al.,31 even though only using culture-
based methods, expressed concern about persistence of resistant
microbes after normalization of the gut microbiota following anti-
biotic exposure. Next-generation sequencing has since confirmed
that antibiotics exert longer-term impacts than previously
thought. Jernberg et al.6 and Lo¨fmark et al.32 described disturb-
ance in the gut Bacteroides community, using culture and PCR
techniques, which persisted for 2 years after a 7 day course of oral
clindamycin (which has notable anti-anaerobe activity). In another
study using 454-pyrosequencing, Jakobsson et al.33 found that the
faecal microbiota was affected for up to 4 years following treat-
ment of Helicobacter pylori infection; high levels of the macrolide
resistance gene ermBwere also found in somepatients.
The gut can therefore act as a reservoir for resistance genes,
with many antimicrobials promoting the emergence of resistance
through their effects on the gutmicrobiota.1,32 Importantly, antibi-
otics selecting for resistant pathogens are not necessarily those
the pathogens are nominally or intuitively resistant to; for ex-
ample, antibiotics other than vancomycin select for the gut expan-
sion of VRE.34 Tulstrup et al.35 recently demonstrated in rats that
metronidazole, cefotaxime and vancomycin altered intestinal per-
meability, although it was unclear as to what extent this affected
themicrobiota or host health; they also found that amoxicillin and
vancomycin initially increase gut bacterial load, presumably owing
to expansion of resistant bacteria. Accurately defining the effects
of antimicrobials, exactly when effects occur, and how different
administration routes impact the gut microbiome using state-of-
the-art genomic techniques is therefore of vital clinical and anti-
microbial stewardship importance. It is also worth noting that an
increase in the expression of AMR genes in the gut microbiota can
occur without direct antibiotic exposure, as was shown in a study
of 35 Swedish students after travel to the Indian peninsula or
Central Africa.36 What drove these changes was unclear, but bac-
terial communities present in the destination environment and
changes in diet are likely to have been factors.
Route of antibiotic administration
Route of administration, antimicrobialmetabolismanddrugexcre-
tion are all thought to be of importance, but our understanding of
these, and their clinical and microbiome implications, remains
sub-optimal.1,28,30,37 Some iv agents are excreted via the biliary
system or secreted by the intestine and, unless reabsorbed, can
potentially have a greater effect on the gutmicrobiome than high-
ly bioavailable oral agents that have no or limited biliary or faecal
excretion (Table 1).37–65 In contrast, oral agents poorly absorbed
from the gastrointestinal tract are likely to affect the gut micro-
biome more than iv agents with low bile or faecal excretion. De
Smet et al.66 recently gave sulfadiazine/trimethoprim to pigs for
5 days by one of three administration routes [oral gavage or via
the feed (both twice daily) or intramuscularly by once-daily injec-
tion]. Blood, faecal and intestinal tissue samples were taken to as-
sess the concentrations of the two components throughout the
bowel. Despite sulphonamides and trimethoprimbeing highly oral-
ly bioavailable and undergoing largely renal excretion, significantly
higher concentrations of sulfadiazine were found in the lower
gastrointestinal tract than trimethoprim, suggesting unrecognized
intestinal secretion of sulfadiazine following absorption. Given that
the prescribing of prolonged oral antimicrobial therapy is likely to
increase as a result of two recently published clinical trials in ortho-
paedic infections and endocarditis,67,68 these results may have
Review
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Table 1. Characteristics of various antibiotics on the WHO Essential Medicines List,38 characterized by administration route and CDI risk
Antibiotic
Oral bioavailability/absorption
(and excretion)
Excretion (including biliary/faecal)
following iv administration
CDI risk (data from NICE evidence sum-
mary comprising three meta-
analysesa)39
Amikacin NA Renal excretion. Low biliary tract con-
centrations versus serum.40
(i) aminoglycosides: no significant as-
sociation seen
(ii) not assessed
(iii) not assessed
Amoxicillin 70% bioavailable.41 Predominantly renal. Detected in biliary
system following iv administration,
but lower concentrations compared
with serum.41,42
(i) penicillins: no significant association
seen (note subgroup analysis
below)
(ii) penicillins: 5 studies: OR 2.71
(95% CI 1.75–4.21)
(iii) penicillins: 4 studies: OR 3.25
(95% CI 1.89–5.57)
Amoxicillin/
clavulanic acid
See above. See above. Clavulanic acid excreted in
urine, bile and faeces.43
(i) subgroup analysis; penicillin com-
bination antibiotics (e.g. co-amoxi-
clav and piperacillin/tazobactam):
6 studies: OR 1.54 (95% CI 1.05–
2.24)
(ii) penicillins: 5 studies: OR 2.71
(95% CI 1.75–4.21)
(iii) penicillins: 4 studies: OR 3.25
(95% CI 1.89–5.57)
Azithromycin 37% plasma bioavailability due to
high tissue binding (rather
than low GI absorption). Biliary
excretion is a major route of
elimination.44
NA (i) macrolides: no significant associ-
ation seen
(ii) macrolides: 4 studies: OR 2.65
(95% CI 1.92–3.64)
(iii) macrolides: 3 studies: OR 2.55
(95% CI 1.91–3.39)
Benzylpenicillin NA Predominantly renal (60%–90%). Biliary
excretion is only a minor fraction.45
(i) see amoxicillin
(ii) see amoxicillin
(iii) see amoxicillin
Cefalexin High.46 Low biliary excretion; predominantly
renal.40,46
(i) subgroup: first-generation cephalo-
sporins, no significant association
seen: OR 1.36 (95% CI 0.92–2.00)
(ii) cephalosporins: 5 studies: OR 5.68
(95% CI 2.12–15.23) (also includes
monobactams and carbapenems)
(iii) cephalosporins: 3 studies: OR 4.47
(95% CI 1.60–12.50)
Cefixime Low (22%–54%); excreted pre-
dominantly unchanged in
urine.47
NA (i) subgroup: third-generation cepha-
losporins, 6 studies: OR 3.20 (95% CI
1.80–5.71)
(ii) see cefalexin
(iii) see cefalexin
Cefotaxime NA Predominantly renal, but high concen-
trations in bile.40,48,49
(i) see cefixime
(ii) see cefixime
(iii) see cefixime
Ceftriaxone NA High unchanged biliary excretion
(40%–50%).40,50
(i) see cefixime
(ii) see cefixime
(iii) see cefixime
Chloramphenicol NA Mostly renal excretion; low active con-
centrations in bile.40
(i) not assessed
(ii) not assessed
(iii) not assessed
Continued
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Table 1. Continued
Antibiotic
Oral bioavailability/absorption
(and excretion)
Excretion (including biliary/faecal)
following iv administration
CDI risk (data from NICE evidence sum-
mary comprising three meta-
analysesa)39
Ciprofloxacin 70%–80% absolute
bioavailability.51
Predominantly renal; 15% via faeces
after iv (mainly intestinal secretion);
1% bile.51,52
(i) quinolones: 10 studies: OR 1.66
(95% CI 1.17–2.35)
(ii) quinolones: 5 studies: OR 5.50
(95% CI 4.26–7.11)
(iii) quinolones: 3 studies: OR 5.65
(95% CI 4.38–7.28)
Clarithromycin High GI absorption. 50% abso-
lute oral bioavailability after
250 mg dose after first-pass
metabolism.53
20%–40% excreted unchanged in urine
(increases with dose increase). 10%–
15% in urine as metabolite. Rest is
excreted in faeces.53
(i) see azithromycin
(ii) see azithromycin
(iii) see azithromycin
Clindamycin High concentrations in bile. 90%
plasma binding. Over 90% ab-
sorption orally (absolute bio-
availability 53%+14% for
600 mg dose).54
10% of the active drug/metabolites are
excreted in the urine, 4% in the fae-
ces; remainder is excreted as inactive
metabolites (predominantly
faecally).54
(i) 6 studies: OR 2.86 (95% CI 2.04–
4.02)
(ii) 3 studies: OR 16.80 (95% CI 7.48–
37.76)
(iii) 2 studies: OR 20.43 (95% CI 8.50–
49.09)
Doxycycline 93%, almost all absorbed in
upper GI tract. Concentrated in
bile. 40% of the dose is elimi-
nated in active form in the
urine, and 32% in the faeces,
after 3 days. High urinary con-
centrations achieved but in the
presence of renal impairment,
urinary elimination decreases
and faecal elimination
increases.55
NA (i) no significant association seen
(ii) no significant association seen
(iii) no significant association seen
(Flu)cloxacillin 79% oral absorption.56 Predominantly renal. 66% if oral, 76% if
parenteral, active drug in urine. Small
amount in bile.56
(i) see amoxicillin
(ii) see amoxicillin
(iii) see amoxicillin
Gentamicin NA Renal excretion. Low bile secretion.40
Shown to have therapeutic concen-
trations in bile with once daily
dosing.57,58
(i) see amikacin
(ii) see amikacin
(iii) see amikacin
Meropenem NA Penetrates biliary tract well.40,59 70%
excreted within 12 h unchanged in
urine; 2% faecal.59
(i) 6 studies: OR 1.84 (95% CI 1.26–
2.68)
(ii) see cefalexin: assessed with cepha-
losporins andmonobactams
(iii) not assessed
Metronidazole Almost complete oral
absorption.60
50% in urine in active form andmetabo-
lites. 20% in faeces.61
(i) not separately assessed
(ii) not separately assessed
(iii) not separately assessed
Nitrofurantoin Rapidly absorbed in upper GI tract
but low serum levels.62
Urinary excretion.62 (i) not separately assessed
(ii) not separately assessed
(iii) not separately assessed
Phenoxymethylpenicillin 60% absorbed.63 Renal excretion. Small amount in bile.63 (i) see benzylpenicillin
(ii) see benzylpenicillin
(iii) see benzylpenicillin
Piperacillin/tazobactam NA High concentrations in bile and 20% bil-
iary excretion.40
(i) see amoxicillin/clavulanic acid
(ii) see amoxicillin/clavulanic acid
(iii) see amoxicillin/clavulanic acid
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implications for clinical practice in humans. They highlight our in-
complete understanding of the excretion ofmany drugs, the asso-
ciated potential gut microbiota effects and the importance of
investigating the effects of alternative and novel routes of antibiot-
ic administration on gutmicrobiota.
Remaining uncertainties in clinical
prescribing
Depending onwhether gutmicrobiota disturbance reaches amax-
imum point, and if so, when this occurs with different agents, it is
likely that shorter courses of antibiotics will impact the gut micro-
biota less thanmore prolonged therapy. Spellberg69 and Llewelyn
et al.70 recently highlighted the limited evidence supporting the
existing antimicrobial-prescribing mantra that a failure to com-
plete a prescribed fixed-length course of antibiotics after clinical
resolution increases the risk of either clinical failure and/or AMR.
The evidence base for shorter courses of antibiotic therapy for
common infections has clearly improved in recent years but
remains inadequate; further research is required to define min-
imum course lengths for common infections of a certain physio-
logical severity that do require antimicrobial therapy, aswell as the
use of biomarkers to guide their durations. Ultimately, we should
be aiming for personalization of antibiotic course lengths in order
tominimize gutmicrobiota exposure and impact whilst optimizing
clinical benefit.
Our overall understanding of the human gut microbiome itself,
however, still remains limited. The Human Microbiome Project71
did not define a ‘healthy’ adult microbiome17 and our knowledge
of the interplay between bacteria, viruses and fungi within the gut
microbiome is poor. It is also recognized that gut antimicrobial ex-
posure may, in certain circumstances, have positive effects
through modification of the gut microbiota. SDD is likely to reduce
mortality by decreasing gut bacterial overgrowth in critically un-
well patients,4,72 but has not been widely implemented, despite a
favourable clinical evidence base, because of unproven fears about
the potential to promote AMR. The use of amoxicillin or cefdinir has
also been shown to improve recovery and decrease mortality in
childrenwith severemalnutrition73 and rifaximin appears tomedi-
ate its beneficial effects in acute or recurrent hepatic encephalop-
athy viamodification of the gutmicrobiome.74 These data suggest
that in certain illness states, including those likely to be associated
with ‘disturbed’ gut microbiota, the potential adverse effects of
antibiotic exposure on the individual and society may be out-
weighed by clinical gains. Fully understanding the effects on the
gut microbiota and beneficial mechanisms of such therapies and
the balance between the benefits to the individual versus any po-
tentialwider negative ecological impact is clearly of importance.
Protecting the gut microbiome from
antimicrobial damage
Antimicrobial prescribing and stewardship
Contemplation of the potential antimicrobial stewardship implica-
tions of the above suggests the need for a more informed and
sophisticated approach to prescribing to optimize gut microbiota
protection. For example, apart from prescribing the narrowest-
spectrum antimicrobial it is clinically safe to use for the shortest
time (a long-accepted stewardship paradigm) it may also be bet-
ter to: (i) prescribe, and develop, iv agents with limited biliary/fae-
cal excretion (Table 138–65); (ii) use oral agents that limit
gastrointestinal tract and gutmicrobiota exposure; (iii) use antimi-
crobials without anti-anaerobic effects when clinically possible; or
even (iv) stop antibiotic therapy altogether rather than switching
from iv to oral when only a small number of further doses are
required and clinical response is unlikely to be affected. In the fu-
ture, there may also be the potential for personalization of drug
dosing by therapeutic drugmonitoring (with the aim of optimizing
efficacy and maximizing suppression of resistance by minimizing
drug exposure) through the use of high-fidelity biomarkers of
Table 1. Continued
Antibiotic
Oral bioavailability/absorption
(and excretion)
Excretion (including biliary/faecal)
following iv administration
CDI risk (data from NICE evidence sum-
mary comprising three meta-
analysesa)39
Sulfamethoxazole/
trimethoprim
Almost 100% absorption.65 Predominantly renal.64 (i) 5 studies: OR 1.78 (95% CI 1.04–
3.05)
(ii) 4 studies: OR 1.81 (95% CI 1.34–
2.43)
(iii) 3 studies: OR 1.84 (95% CI 1.48–
2.29)
Vancomycin Not usually absorbed in the blood
after oral administration (un-
less bowel wall injury is pre-
sent, e.g. pseudomembranous
colitis).65
Parenteral: predominantly renal, with
only 5% biliary. Oral: very low in urine.
High concentrations in faeces.65
(i) not separately assessed
(ii) not separately assessed
(iii) not separately assessed
GI, gastrointestinal; NA, not applicable.
aNICE evidence summary of CDI risk with broad-spectrum antibiotics. Compiled data from three meta-analyses: (i) Slimings and Riley (2014)89
reviewed hospital-associated CDI; (ii) Brown et al. (2013)90 reviewed community-associated CDI; and (iii) Deshpande et al. (2013)75 reviewed commu-
nity-associated CDI.
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patient recovery as a means of limiting gut antibiotic exposure.
For patients in whom these goals are unachievable, mitigation by
gut microbiome protection using yet-to-be-developed therapeu-
tics, such as next-generation faecal microbiota transplantation
(FMT) or probiotics,may bewarranted.
Microbiome protection therapies
Both FMT and probiotics have shown promise as gut microbiome
therapies to mitigate the negative effects of antibiotic exposure. C.
difficile infection (CDI) has long been known to be associated with
antimicrobial prescribing.75 Despite first being used in 1958, and
with subsequent reports suggesting an90% cure rate in recurrent
CDI,76 the first randomized controlled trial of FMTwasonly reported
by van Nood et al. in 2013.77 This trial was relatively small but was
stopped early owing to the marked benefits of FMT versus oral
vancomycin. Despite this, FMT is yet to be widely implemented in
clinical practice, possibly owing to the considerable challenges of
use and because the full risks and benefits continue to be debated
and investigated. Interestingly, Staley et al.78 recently found that
bacteria associated with secondary bile acid metabolism provide
the gut with resistance to CDI, again highlighting the potential im-
portance of protecting the commensal bacteria of the small intes-
tine. The role, if any, of pre- or post-exposure FMT as primary
prophylaxis is currently unclear, but it may have potential once the
residual concerns about FMT have been resolved and it has evolved
into amore easily administered therapy (e.g. in oral pill form).
One recent systematic review found that administration of pro-
biotics within 2 days of the first dose of antibiotic treatment
reduced the risk of CDI by .50% (from 3.9% to 1.6%) and early
commencement of probiotics at the time of starting antibiotics
was likely to be important. There was no significant difference
found between the doses, species or formulations studied.79 The
potential impact of such approaches onmitigating the risk of a pa-
tient becoming colonized or infected with antimicrobial-resistant
bacteria, or suffering other non-infection health problems, is also
unclear, but is theoretically attractive. The development of rapid,
inexpensive tests that can quickly identify possible health-
impacting disturbance of the gutmicrobiotamay be of importance
in future clinical practice. Such tests would identify at-risk patients
exposed to a range of interventions (not necessarily just antibiot-
ics) and enable physicians to cost-effectively target microbiome
protective therapies to thosemost likely to benefit.
A different, but elegant approach is the chemical trapping of
vancomycin in the gut, which has been found to prevent the selec-
tion of VRE in vitro.80 The use of oral b-lactamases, administered
alongside iv b-lactam antibiotics in order to assist the breakdown
of antibiotic(s) entering the gut (thereby preserving the micro-
biome and preventing CDI andother negative effects), is also being
investigated: it appears to be an attractive strategy for current and
future iv b-lactam agents withmicrobiota-impacting biliary or fae-
cal drug excretion.81 In the future, such considerations and the
effects of new agents on the health of the gut microbiome should
be incorporated, investigated and publicly reported as part of anti-
microbial drug development.82
Avoiding the gut microbiome in treatment
Topical preparations, and local administration, of antibiotics have
long been used to treat acute and chronic skin, ear and eye
infections, and have been used prophylactically to reduce the risk
of surgical site infection (SSI).83 Whilst topical or local administra-
tion is accepted clinical practice in certain situations (e.g. gentami-
cin within cement in elective primary joint replacement), use in
other clinical scenarios, for example to prevent SSI after colonic
surgery or in the treatment of orthopaedic infections, remains con-
troversial. This is often owing to concerns regarding efficacy and
the potential for topical agents to encourage AMR or cause local
adverse effects, such as rash or itching.84 There is therefore a need
to synthesize published data and perform further research to iden-
tify niches in clinical practice where topical or local administration
of antibiotics can reduce or avoid the need for systemic therapy
and subsequent gut exposure.
Related to topical and local use of antimicrobials is transdermal
administration using dissolvable microneedle patches. Proof-of-
principle studies have shown that antibiotics can be successfully
administered via this route inmice, leading to systemic concentra-
tions above the MIC of potential target bacteria.85 For this route of
administration to reduce gutmicrobiome exposure, however, anti-
biotics that have low or no biliary or faecal excretionwill need to be
utilized.
Nebulized administration also has the potential to limit gut
antimicrobial exposure, particularly in patients with chronic lung
conditions such as cystic fibrosis, a cohort often exposed to sys-
temic therapy. Wenzler et al.86 highlighted, however, the lack of
comparative data and controlled trials in this area. As with trans-
dermal administration, there is also the potential for this route to
be used for the treatment of non-lung infections, although
pharmacological anddrug-delivery challenges remain.87 There are
also few data on the relationships between the human lung and
gut microbiomes and how the latter may be altered by inhaled
antimicrobial administration, either by direct ‘leaking’ into the oe-
sophagus during exposure or via biliary excretion of any agent sub-
sequently entering the systemic circulation.
Use of precision, very-narrow-spectrum agents
The traditional approach to the development of systemic anti-
microbial agents has been to develop broad-spectrum ‘block-
buster’ agents that have activity against a wide range of
pathogens, but also have considerable ecological adverse effects
on human and environmental flora. From a microbiome and AMR
perspective, the development of very-narrow-spectrum agents
that target a limited number of pathogens (or only one), and
therefore impact the human microbiome less, is highly attractive;
however, this approach is unlikely to lead to an adequate return on
investment for developers within the existing reimbursement
framework. Nevertheless, some agents, such as fidaxomicin for
CDI, have been brought to market successfully or are in develop-
ment.88 The key to using such drugs cost-effectively, however, will
be the development of highly accurate, rapid diagnostics that can
bedeployed at the bedside or in the clinic.
Conclusions
Although culture and metagenomic methods have considerably
improved our knowledge regarding the effects of antimicrobials on
the gutmicrobiota and the associated risk of AMR gene expression,
further research is clearly required. If we are to preserve existing
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and new antimicrobials, we need to consider their use in the con-
text of their effect on gut ecology, and the human microbiome in
general. We also need to challenge existing prescribing paradigms
by establishing the clinical evidence base for alternative
approaches, such as short-course therapy, stopping iv therapy
without an oral switch and alternative routes of administration. The
gut microbiome, and approaches to mitigating any negative im-
pact, should be considered during antimicrobial drug development.
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